Cetera Investment Advisers Acquires 5,769 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Cetera Investment Advisers increased its holdings in LeMaitre Vascular, Inc. by 209.6% in Q1, resulting in ownership of 8,522 shares valued at $715,000.
• LeMaitre Vascular reported $0.60 earnings per share for the last quarter, surpassing estimates by $0.03, with a revenue increase of 15% year-over-year.
• The company declared a quarterly dividend of $0.20, representing an annualized yield of 0.8%, and has a current dividend payout ratio of 38.83%.

Cetera Investment Advisers increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 209.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,522 shares of the medical instruments supplier's stock after acquiring an additional 5,769 shares during the quarter. Cetera Investment Advisers' holdings in LeMaitre Vascular were worth $715,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Alliancebernstein L.P. lifted its position in shares of LeMaitre Vascular by 6.0% in the 4th quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock valued at $2,081,000 after acquiring an additional 1,287 shares in the last quarter. Wells Fargo & Company MN raised its stake in LeMaitre Vascular by 8.8% during the 4th quarter. Wells Fargo & Company MN now owns 28,153 shares of the medical instruments supplier's stock valued at $2,594,000 after purchasing an additional 2,274 shares during the period. Bank of Montreal Can boosted its position in shares of LeMaitre Vascular by 8.3% in the fourth quarter. Bank of Montreal Can now owns 2,926 shares of the medical instruments supplier's stock worth $270,000 after buying an additional 223 shares during the period. Invesco Ltd. grew its holdings in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after buying an additional 58,720 shares in the last quarter. Finally, Legal & General Group Plc raised its position in LeMaitre Vascular by 2.4% during the fourth quarter. Legal & General Group Plc now owns 57,753 shares of the medical instruments supplier's stock valued at $5,321,000 after buying an additional 1,339 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 0.6%

NASDAQ:LMAT traded up $0.58 during mid-day trading on Tuesday, reaching $95.62. The stock had a trading volume of 8,288 shares, compared to its average volume of 188,511. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The stock has a market cap of $2.16 billion, a P/E ratio of 46.42, a PEG ratio of 2.47 and a beta of 0.79. The business's 50 day moving average is $84.79 and its 200 day moving average is $86.33. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular's revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's payout ratio is 38.83%.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of research reports. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald boosted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $98.00.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $94.00, for a total transaction of $235,000.00. Following the transaction, the director owned 2,916 shares in the company, valued at $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John A. Roush sold 6,561 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director owned 2,916 shares of the company's stock, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 120,815 shares of company stock valued at $11,280,206 in the last quarter. Company insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.